Abstract: There is growing evidence for the existence of not only homomeric, but also functional heteromeric receptor complexes, particularly involving G protein coupled receptors (GPCRs). These include adenosine A 2A -dopamine D 2 and adenosine A 2A -glutamate mGlu 5 receptor complexes. The role of these receptor complexes in receptor function seems to be multiple, involving hetero-modulation of ligand recognition, signalling and trafficking. The preferential localization of A 2A -D 2 and A 2A -mGlu 5 receptor complexes is in the dendritic spines of striatopallidal GABAergic neurons. Results obtained from behavioral and in vivo microdialysis experiments have shown an important role of mGlu 5 -A 2A -D 2 receptor interactions in the modulation of the function of the striatopallidal GABAergic neurons. The striatopallidal GABAergic neurons play a key role in the pathophysiology of basal ganglia disorders, like Parkinson's disease, and it is a common pathway for the rewarding effects of opiates and psychostimulants and for the antipsychotic effects of neuroleptics. The formation of receptor complexes modifies the single receptor transducing characteristics and leads to the appearance of "emergent properties". Thus, the study of mGlu 5 -A 2A -D 2 receptor interactions in the striatum reveals new properties of these GPCRs and gives indications for a new rational approach for drug therapy in neuro-psychiatric disorders and drug addiction.
INTRODUCTION
The basic tenet of the present paper is that the G protein coupled receptors (GPCRs or heptahelical receptors) should be considered not only as single units, but also, frequently, as multimolecular aggregates (see the "receptor mosaic hypothesis", refs. [1, 2] ). In other words, in most instances GPCRs are functionally connected with other molecules either intrinsic to the plasma membrane or associated with the extracellular or intracellular surface of the membrane. The function of each GPCR can be markedly affected by its interactions with different molecules (especially proteins). "Receptor-receptor interactions" represent a special type of these interactions [1] [2] [3] [4] . In the present paper three GPCRs (glutamate mGlu 5 , adenosine A 2A and dopamine D 2 receptors) will be examined. In a first instance, each receptor will be examined as single decoding unit, thereafter the emergent properties of the receptor complexes due to mGlu 5 -A 2A -D 2 receptor interactions will be discussed. The main *Address correspondence to this author at the Preclinical Pharmacology Section, Department of Health and Human Services, NIH, NIDA, IRP, 5500 Nathan Shock Drive, Baltimore MD 21224, USA; Tel: 410-550-1586; Fax: 410-550-1648; E-mail: sferre@intra.nida.nih.gov focus will be on the receptors in the striatopallidal neuron, where there is clear-cut evidence that mGlu 5 , A 2A and D 2 receptors interact. Molecular aspects of these interactions have been evaluated, as well as some of the physiopathological counterparts of these molecular mechanisms have been described [2, 5, 6] . It is also obvious that on the basis of the experimental evidence presented it is possible to surmise strategies to develop new drugs that may be capable of acting with more selectivity on GPCRs and, thus, to avoid some side-effects of drugs currently in use. For the sake of clarity, some basic aspects of GPCRs will be briefly presented. These aspects should also allow a better understanding of our view and of our hypothesis.
Some Molecular and Functional Features of GPCRs
It should be noticed that GPCRs span three environments: the extracellular, the intramembrane and the intracellular. Each of these environments has peculiar characteristics (lipophilicity versus hydrophilicity, ion activity, electrostatic fields,…) that obviously affect the steric conformation of the strand of amino acids crossing through it. Four main aspects should be considered:
The relative topologies of the amino acid domains of the receptors with respect to the other domains, since this aspect leads to the particular steric structure (folding) of the receptor.
The domains of the GPCR that allow the interactions with other molecules in one of the three environments spanned by the receptor, especially the so-called binding pocket for the transmitter and the binding domain for G proteins and also for some scaffold proteins as well as for other receptors.
The trafficking of the receptor with its appearance at cell membrane level, where it can act as a molecular transducer, i.e., as a molecular mediator that links the extracellular signal with the molecular intracellular effector. This aspect will be examined only by considering the receptor internalization phenomenon.
The functional state of the receptor that allows its action as transducer and, therefore, the effectiveness according to which the receptor transduces the signal. This aspect will be examined only by considering receptor sensitization and desensitization phenomena.
GPCR Families
GPCRs comprise the largest family of membrane-bound receptors, representing more than 1% of the genome in vertebrates [7, 8] . All GPCRs have in common a central core domain constituted by seven transmembrane (7TM) domains that are connected by three intracellular and three extracellular loops, an extracellular N-terminal segment and an intracellular C-terminal segment. Each of the 7TM domains is composed of 20-27 amino acids. On the other hand, N-terminal and C-terminal segments and the intra-and extracellular loops can vary very much in size. Most GPCRs can be grouped in three major families, according to sequence differences. Family I (or Family A) contains most GPCRs, including receptors for rhodopsin, catecholamines and adenosine (subgroup 1a), the binding site of which is made by a cavity formed in the 7TM region. Rhodopsin is a particular case, where the target of photons, retinal, is covalently linked in this cavity and converted into an active ligand upon light exposure. Other members of Family I (subgroups 1b and 1c) are activated by short peptides or glycoproteins that also bind to the N-terminal segment of the receptor (large in case of subgroup 1c). Family II (or Family B) comprises GPCRs that are activated by large peptides, like glucagon, calcitonin or VIP (vasoactive intestinal peptide), which bind to a relatively large N-terminal domain. Finally, family III (or Family C) includes metabotropic glutamate (mGlu) receptors, a receptor activated by extracellular Ca 2+ (calcium sensing receptor) and GABA B receptors [7, 8] . Family III receptors contain a very large Nterminal segment that forms two distinct lobes facing each other and separated by a cavity where the ligand binds. The results of a series of studies, including the determination of the crystal structure of the N-terminal domain of mGlu 1 receptors suggest that the two lobes close like a "Venus flytrap" upon binding of the ligand [9, 10] . Including Family III, irrespective of the localization of the ligand binding domain, a change in conformation of the 7TM core region is the most probable mechanism responsible for receptor activation in all GPCRs [7, 8, 10] .
The change in conformation of the core domain affects the conformation of the intracellular loops, which determines the binding and activation of G proteins. Activation of G proteins is then responsible for activation of different intracellular signaling pathways [8, 11] . However, different classes of proteins, other than G proteins, are being recognized to interact with GPCRs. The binding of GPCRs to some of these proteins will determine interactions with different intramembrane and intracellular elements, which will result not only in changes in receptor localization and function but also in G protein-independent signalling [9, [11] [12] [13] [14] . These proteins include serine-threonine or tyrosine protein kinases, β-arrestins, Homer proteins and other proteins localized in the postsynaptic density (see below). However, they also include GPCRs themselves, which gives the possibility of the formation of GPCR homo-and heteromeric complexes (see below).
Internalization of GPCRs
Receptor desensitization, the decrease of receptor responsiveness to agonist, represents an adaptive mechanism that protects the receptor against acute and chronic overstimulation. However, GPCR desensitization can also limit the therapeutic usefulness of receptor agonists. GPCR desensitization is the consequence of different mechanisms that in many cases include the phosphorylation-induced uncoupling of the receptor from G proteins, the internalization of cell surface receptors to intracellular compartments, and the down-regulation of the total amount of receptors as a result of receptor degradation and/or decreased synthesis. These mechanisms have different time frames, which range from seconds (phosphorylation) to minutes (internalization) or hours (down-regulation) [12, 14, 15] . Phosphorylation of serine and threonine residues within the intracellular loops and C-terminal segment of GPCRs can be induced by either GPCR kinases (GRKs) or by second messenger-dependent protein kinases (such as protein kinase A [PKA] and protein kinase C [PKC] ). GRKs are made of seven family members that can be classified into three groups according to sequence and function homology: GRK1 and GRK7; GRK2 and GRK 3; GRK4, GRK5 and GRK6) [12] . GRKs selectively phosphorylate activated receptors and, therefore, induce acute homologous desensitization. On the other hand, second messengerdependent protein kinases induce both acute homologous and heterologous sensitization, since they can indiscriminately phosphorylate agonist-activated and nonactivated receptors [12] .
Acute homologous desensitization induced by GRK is the first step in the process of receptor internalization dependent on arrestins. Arrestin proteins bind preferentially to agonist-activated and GRK-phosphorylated GPCRs, as opposed to second messenger protein kinase-phosphorylated or non-phosphorylated receptors. When bound to the receptor, arrestins physically prevent the receptor-G protein association, "arresting" the receptor in the desensitized G protein uncoupled state initially induced by GRK-mediated phosphorylation. Furthermore, arrestins will bind several molecules involved in receptor internalization, such as clathrin, AP-2 and N-ethylmaleimide-sensitive fusion protein (NSF) [12, 14] . In this way, arrestins serve as adapters that target GPCRs for internalization through clathrin-coated pits. Four arrestin family members have been identified and classified into two groups based on sequence homology and tissue distribution: visual arrestins (visual arrestin and cone arrestin) and β-arrestins [12, 14] . The two identified β-arrestins, β-arrestin 1 and β-arrestin 2, have been shown to have different properties [16, 17] . Two different classes of GPCRs (which have no relation with the above mentioned GPCR families) have been proposed according to their differential interaction with β-arrestin 1 and β-arrestin 2 [16] . Thus, class A GPCRs, that include β 2 and α 1b adrenergic receptors, µ-opioid receptors, endothelin type 1A receptor and some dopamine receptor subtypes, interact with β-arrestin 2 with higher affinity than with β-arrestin 1 [16, 18] . On the other hand, class B GPCRs, that include angiotensin type 1 receptor, vasopressin type 2, neurotensin receptor, neurokinin type 1 receptor and thyrotropinreleasing hormone receptor show high affinity for both proteins [16] .
Although much has been learned about the desensitization mechanisms that take place during the first seconds or minutes after agonist exposure, little is known about the mechanisms that are involved after longer time of exposure. These, in fact, are the most relevant when considering the therapeutic and secondary effects of exogenous agonists. Although there is a rapid reversibility of the initial processes of desensitization (phosphorylation and initial internalization), down-regulation is characterized by slow or incomplete reversibility following removal of the agonist. The most accepted general mechanism is that once the receptors are internalized they are targeted to "early" endosomes, where they can undergo dephosphorylation and recycling to the plasma membrane (resensitization) or they are further targeted to "late" endosomes or lysosomes for degradation [15] . This model explains the usual dependence of internalization for GPCR resensitization. The "late" endosomes step appears to play an important role in promoting down-regulation of certain GPCRs [15] . However, receptor-specific and cell-specific mechanisms of GPCR endocytosis other than the GRK/β-arrestins/clathrincoated pits seem to exist. For example, some GPCRs have also been shown to internalize in a β-arrestin-independent manner, by means of small invaginations of the plasma membrane called caveolae (see below). Differential rates of internalization, resensitization and down-regulation together with the rate of receptor synthesis determine the characteristic turnover and, therefore, surface expression of receptors. In some cases, even agonist-induced "upregulation" can be observed, as found with some subtypes of dopamine receptors (D 2L and D 3 receptors; see below).
Although initially they were thought to be exclusively involved in receptor desensitization and internalization, β-arrestins have been recently shown to play a key role in G protein independent signaling of GPCRs and, in particular, in GPCR-mediated mitogen-activated protein kinases (MAPKs) activation [19, 20] . Thus, in addition to binding different elements involved in receptor internalization, β-arrestins also seem to act as scaffold adapters that coordinate the formation of multiprotein signaling complexes that ultimately lead to activation of MAPKs [19, 20] . The assemby of a multiprotein complex at the plasma membrane, which includes receptor and non-receptor tyrosine kinases, allows signal transduction from activated GPCRs to the cytosol located MAPKs, such as extracellular signal-regulated kinases 1 and 2 (ERK1 and 2; in this review, the term MAPK makes reference to ERK1 and 2). This multiprotein complex leads to activation of the small G-protein Ras, which leads to the sequential phosphorylation and activation of the MAPKKK Raf-1, the MAPKK MEK and, finally, MAPK. The coordinating role of β-arrestins on the formation of the multiprotein complex seems to depend on direct interactions with the non-receptor tyrosine kinase Src and other members of the MAPK activation pathway, such as Raf-1 and ERK1 and 2 [19, 20] . Src also plays a key dual role in GPCR function, as activator of MAPK signaling [13] and as a required element in agonist-induced receptor endocytosis. Src-mediated tyrosine phosphorylation of dynamin seems to be essential for the well-known role of this protein in constriction of clathrincoated pits and fission of vesicles [21] . Finally, Src can be activated, not only by binding to β-arrestins, but also by direct interactions with G proteins (Gi and Go, but not Gq) and GPCRs themselves [22, 23] . Consequently, β-arrestin binding to the agonist-activated and GRK-phosphorylated GPCR not only terminates receptor-G protein coupling, and therefore, G protein mediated signal transduction, but also initiates a second signal transduction leading to MAPK activation. Thus, by targeting the appropriate multiprotein complexes to clathrin-coated pits, β-arrestins establish a link between MAPK signaling and receptor internalization. In fact, in some systems internalization of signaling protein complexes that include the activated receptor seems to be an additional requirement for MAPK activation, sometimes associated with transactivation of receptor tyrosine kinases [19, 20, 24, 25] . Their association with endocytic vesicles may provide a mechanism for targeting signaling protein complexes to appropriate subcellular localizations, determining if MAPK phosphorylate membrane, cytosolic or nuclear targets [20] . In fact, MAPK plays a predominant role in the mailing of signals from the synapse to the nucleus, since downstream direct or indirect effectors of MAPK are nuclear constitutive transcription factors such as CREB and Elk-1 (see below).
Caveolae were initially identified as flask-shaped plasma membrane invaginations. However, the cloning and characterization of a biochemical marker for caveolae, caveolin, demonstrated the existence of caveolin-rich membrane microdomains that could not be distinguished morphologically from the rest of the plasma membrane [26] [27] [28] [29] . The caveolin family comprises a group of proteins (caveolin-1, caveolin-2, with two and three isoforms, respectively, and caveolin-3) encoded by three genes [27, 28] . Caveolins are the major component of caveolae and their oligomerization seems to be essential for the formation of the caveolar coat. However, a particular lipid environment, enriched in cholesterol and sphingolipids, is also required for the formation of caveolae [27, 28] . Clustering of these lipids constitute specialized detergent insoluble membrane domains initially called lipid rafts. The "raft hypothesis", as proposed by Simons et al. [30, 31] , postulates the existence of lateral assemblies (rafts) of sphingolipids and cholesterol, which associate with specific proteins while excluding others. Rafts would concentrate signaling and associated molecules within the same plasma cellular domain. Caveolae therefore, are considered to be a specialized form of raft that contains caveolin proteins [26, 29] . Caveolin-reach rafts have been shown to be enriched in a variety of signaling molecules, which includes G protein subunits, nitric-oxide synthase and a variety of receptor and non receptor tyrosine kinases (epidermal growth factor [EGF] receptor, platelet-derived growth factor [PDGF] receptor, insulin receptor and Src-related kinases), serinethreonine kinases (GRK, PKA, PKC), and tyrosine-serinethreonine kinases (MAPK). Most of these signaling molecules, in fact, interact directly with caveolin, particularly with a short caveolin cytosolic domain (caveolin-scaffolding domain, or CSD) [27, 28] . Besides receptor tyrosine kinases, a fast increasing number of GPCRs are being shown to aggregate, sometimes upon agonist binding, in caveolae. Among others, this includes adenosine A 1 receptors [32] and, so far, two receptors of family III GPCRs: mGlu 1 receptors [33] and calcium sensing receptor [34] . Furthermore, we have recently found evidence for co-localization of adenosine A 2A and dopamine D 2 receptors with caveolin in CHO cells stably transfected with both receptors (Agnati et al. in preparation) . Their capacity to concentrate an important number of signaling molecules in a discrete cellular location supports the point of view that caveolae are important functional structures involved in the control of cell signaling [27, 28] .
As mentioned above, caveolae have also been implicated in GPCR internalization, which may therefore lead to desensitization and to internalization-related signaling. Furthermore, they have been involved in homologous and heterologous GPCR desensitization by a mechanism involving a transient sequestration of receptor by direct binding of activated G protein subunits to caveolins [35] . Co-sequestration of different receptors might lead to heterologous desensitization, a phenomenon recently demonstrated for EGF and PDGF receptors [36] and for adenosine A 2A and dopamine D 2 receptors [37] . The involvement of clathrin and/or caveolin-coated vesicles in this A 2A -D 2 receptor co-internalization still needs to be determined, although, as indicated above, we have found evidence for co-localization of adenosine A 2A and dopamine D 2 receptors with caveolin in a CHO cell line (Agnati et al. in preparation) . However, caveolins seem to be expressed in low levels in the brain, where they predominate in nonneuronal cells (endothelial cells and astrocytes) [38, 39] . Nevertheless, evidence is accumulating which suggests that non-caveolin lipid rafts are abundant in the brain and play very similar roles as caveolae play. Furthermore, proteins functionally similar to caveolins, such as flotillins, are being found in non-caveolin lipid rafts [40] . Specially relevant for the present review is the recent work by Suzuki and coworkers [41, 42] . Their results suggest a predominant localization of flotillin lipid rafts in dendritic spines (dendritic rafts) with a postsynaptic and perisynaptic distribution and with direct interactions with the postsynaptic density (see below). Finally, their results also showed the existence of AMPA glutamate receptors in the dendritic rafts, suggesting their involvement in the trafficking of AMPA receptors and, therefore, in synaptic plasticity [41, 42] .
PHYSIOLOGY OF GLUTAMATE mGLU 5 RECEP-TORS
Glutamate is the main excitatory neurotransmitter in the mammalian central nervous system. Dendritic spines are the preferential site of excitatory synaptic connections and nearly all presynaptic terminals that make synapses on dendritic spines release glutamate. Rapid excitatory synaptic transmission is mediated primarily by the actions of glutamate on two types of ionotropic receptors: AMPA and NMDA. These receptors are mostly localized on the postsynaptic density, an ultrastructurally defined electrondense thickening of the postsynaptic membrane of the dendritic spines [43, [44] [45] [46] . In addition to ionotropic glutamate receptors, the postsynaptic density is made of a protein lattice that includes many different organized assemblies of specific proteins. Postsynaptic density proteins are not only involved in signaling, but in the dynamic regulation of different elements of the dendritic spine (including the postsynaptic density itself), which causes both functional and morphological changes that might underlie synaptic plasticity [43] [44] [45] [46] [47] . Those changes include local dendritic translation of mRNA [48] , phosphorylation and redistribution (exocytosis-endocytosis) of ionotropic receptors [49] [50] [51] [52] and changes in dendritic spine cytoskeletal structures [47, [53] [54] [55] .
In addition to its ionotropic AMPA, NMDA and kainate receptors, which mediate fast excitatory glutamate responses, glutamate has metabotropic receptors (mGlu receptors, prototype of Family III GPCRs) that mediate slower, modulatory, responses by coupling with multiple intracellular signalling cascades. Based on sequence similarities, preferred signal transduction mechanisms and pharmacological properties, the 8 subtypes of mGlu receptors so far identified are subdivided into three groups. Group I mGlu receptors includes mGlu 1 receptors, with four isoforms (mGlu 1a and the short isoforms mGlu 1b , mGlu 1c and mGlu 1d receptors), and mGlu 5 receptors, with two isoforms [10, 56] . In the same way as ionotropic glutamate receptors, Group I mGlu receptors also show a predominant and characteristic postsynaptic localization at glutamatergic synapses. Thus, Group I mGlu receptors are localized in a perisynaptic ring adjacent to the postsynaptic density [57, 58] . This localization seems to depend mainly on the existence of specific protein-protein interactions that involve postsynaptic density proteins, such as PSD-95 and Shank [43] [44] [45] [46] . PSD-95 is a scaffold protein that binds directly with the C-terminal portion of NR2 subunit of the NMDA receptor; thus, it may be important for clustering of NMDA receptors at synapses [59] . PSD-95 is included on a family of synaptic membrane-associated proteins that are collectively termed membrane-associated guanylyl kinase (MAGUK) proteins [44] . Shank comprises a family of scaffold proteins that contains multiple sites for protein-protein interactions and which is concentrated in a deeper part of the postsynaptic density than is PSD-95 [60] . The connection between Shank and PSD-95 is made by guanylate kinaseassociated protein (GKAP), which constitutes another abundant family of postsynaptic density proteins [60] . Finally, Shank binds to Homer proteins, which selectively binds Group I mGlu receptors [61] . Through these interactions NMDA and Group I mGlu receptors are physically connected. In fact, there is evidence for synergistic NMDA receptor interactions with Group I mGlu receptor interactions, the most common being a potentiation of NMDA-mediated responses by mGlu 5 receptor stimulation (see below and refs. [62] [63] [64] ). In addition, NMDA receptor activation seems to be required for some effects of mGlu 5 receptor activation (see below). As discussed below, there is also evidence for an NMDA receptor-mediated potentiation of mGlu 5 receptor function, by reversal of basal PKC-induced mGlu 5 receptor desensitization [65] .
Three main genes encoding Homer proteins have been identified; they generate diverse isoforms by alternative splicing [66] . Homer proteins are characterized by a highly conserved N-terminal EVH1 domain. This EVH1 domain binds to a distal, proline-rich region of the C-terminal portion of mGlu 5 receptor (both isoforms) and the long isoform of mGlu 1 receptor [66, 67] . On the other hand, Homer proteins do not bind to Group II or III mGlu receptors [66, 67] . The same EVH1 domain is responsible for the Homer-Shank interaction [61, 66] and for the direct interaction with inositol triphosphate (IP3) and ryanodine receptors, which are localized in the endoplasmic reticulum [61, 66] . In addition to the EVH1 domain most Homer proteins contain a coiled-coil C-terminal domain (CC domain), which mediates both homomeric and heteromeric association among the different isoforms [66] . The CC domain, therefore, confers the functional capacity of crosslinking Group I mGlu receptors and related Homer interacting proteins, like Shank and IP3 and ryanodine receptors. In addition to the constitutively expressed Homer 1b and Homer 1c, the Homer 1 gene can also generate two short isoforms which lack the CC domain. These short-form isoforms, called Homer 1a and Ania 3, are immediate-early gene (IEG) products the transcription of which is increased with neuronal activation [67, 68] . Glutamate receptor (specially NMDA receptor) activation has also been shown to induce Homer 1a expression [69, 70] , involving MAPK signaling [70] . The Homer 1 gene contains 10 exons for the alternatively spliced constitutive forms, Homer 1b/c, while Homer 1a and Ania 3 end within the 5 intron, that separates the exons encoding the N-terminal EVH1 domain (exons 1-5) from those encoding the CC domain (exons 6-10) [68] . Bottai et al. have recently shown that there is a switch from the constitutive expression of Homer 1b/c to the activitydependent expression of Homer 1a and Ania 3, which entails intronic to exonic sequence conversion and transcript termination within the central intron of the Homer 1 gene [68] .
By counteracting CC-oligomerization of long isoforms, the Homer IEG products are natural competitive antagonists of the constitutive long-form isoforms and their expression disrupts the coupling of Group I mGlu receptors to other Homer interacting proteins [69, 71] . This implies modifications of mGlu receptor signalling and trafficking.
For both mGlu 1 and mGlu 5 receptors an increased Homer 1a expression unmasks an agonist-independent, constitutive activity of the receptor [69, 72] . Homer 1a acts as an indirect Group I mGlu receptor agonist. The effects on trafficking, however, depend on the mGlu receptor subtype. Recent experimental findings strongly suggest that Homer 1b and Homer 1c cause a retention of mGlu 5 receptors in the endoplasmic reticulum (ER), and Homer 1a triggers the trafficking of mGlu 5 receptors to the plasma membrane [72] [73] [74] . ER retention induced by the long Homer isoforms could be just related to their ability to cross-link mGlu 5 receptors to the ER proteins IP3 and ryanodine receptors. For different GPCRs homo-and heteromerization seems to be a prerequisite for exiting the ER. With the formation of the GPCR dimer the amino acid sequences involved in ER retention (directly or through additional proteins, such as the long Homer isoforms) would be hidden. In fact, Coutinho et al. showed that Homer 1c prevents mGlu 5 receptor homodimerization [74] . In contrast to mGlu 5 receptors, both Homer 1a and Homer 1c have been reported to increase cell surface clustering of mGlu 1a receptors [75, 76] . Thus, a differential Homer-mediated regulation between mGlu 5 and mGlu 1 receptor trafficking seems to exist. In this way the levels of constitutive and inducible Homer proteins might determine the predominant mGlu receptor subtype expressed at the surface of cells containing both receptors.
Group I mGlu receptors couple preferentially to phospholipase C (PLC) through coupling to Gq proteins (see Fig. (1) ). Activation of PLC induces a release of inositol (1,4,5)triphosphate (IP3) and diacylglycerol (DAG), which cause the release of intracellular Ca 2+ and the activation of protein kinase C (PKC), respectively [10, 77] . In addition to the preferential Gq-PLC pathway, Group I mGlu receptors have also been shown to use other signaling pathways, such as adenylyl cyclase [78, 79] and MAPK [80, 81] pathways. Work by Francesconi and Duvoisin [78, 79] suggests that Group I mGlu receptors stimulate adenylyl cyclase by their ability to couple to Gs proteins. Depending on the cellular system used, Group I mGlu receptor-mediated MAPK activation can be dependent on or independent of PKC activation and, therefore, dependent on or independent of the initial activation of PLC pathway. In either case, activation of non-receptor tyrosine kinases seems to be required. Among the different major gene families of non-receptor tyrosine kinases so far identified the protein products of the c-src family, such as Src and Fyn, have been the most extensively studied. However, other non-receptor tyrosine kinases, such as the cell-adhesion kinase β (CAKβ; also called Pyk2, FAK-2, CADTK or RAFTK), which belongs to the focal adhesion (FAK) family, seem to play an important role in glutamatergic synapses [82] . There is evidence showing that Src, Fyn and CAKβ are specially concentrated in the postsynaptic density and that PKC or an increased extracellular Ca 2+ lead to Src activation secondarily to CAKβ phosphorylation [82, 83] . This cascade of events have been implicated in the above-mentioned Group I mGlu receptormediated potentiation of NMDA receptor function [84] [85] [86] . In fact, the NMDA receptor subunit 2B (NR2B) is the major tyrosine phosphorylated protein of the postsynaptic density fraction [87] . Furthermore, a recent study by Choe and Wang suggests that NMDA receptors are involved in the activation of MAPK and the constitutive transcription factors CREB (cAMP response element binding protein) and Elk-1 induced by the stimulation of Group I mGlu receptors in the striatum [88] . Both PKC and Ca 2+ /calmodulin-dependent protein kinases (CAMK) were also involved [88] Fig. (1) and PKC-independent but dependent on Gq protein activation, transactivation of a receptor tyrosine kinase (EGF receptor) and activation of Src [81] . Their results, which included mGlu 5 receptor agonist-induced coimmunoprecipitation of EGF and mGlu 5 receptors, are consistent with the formation of multiprotein signaling complexes leading to MAPK activation (see above and refs. [19, 20] ). Finally, a G protein-independent and Src-dependent signaling mediated by Group I mGlu receptors has also been reported [89] . This might be related to a β-arrestin-Src interaction (see above), since Group I mGlu receptors have been shown to interact with β-arrestins and to undergo agonist-induced GRK/β-arrestin-dependent internalization [90, 91] (Fig. (1) ).
CAMK comprises a group of kinases that have been shown to be involved in the coupling of synaptic activity (Ca 2+ influx through NMDA receptors) to synaptic plasticity (long-term potentiation [LTP] and long-term depression [LTD]) at glutamatergic synapses [46, 50, [92] [93] [94] . Stimulation of NMDA receptors, by increasing Ca 2+ entry and binding to calmodulin, induces activation of CaMKII, which causes its translocation to the postsynaptic density and its binding to NMDA receptors (preferentially to NR2B). Once the interaction with NMDA receptors is established, Ca 2+ and calmodulin are no longer required for CaMKII to be activated and NR2B-bound CaMKII remains partially active even after calmodulin dissociation, which might serve as a form of "molecular memory" of a previous brief stimulation [94, 95] . The postsynaptic density protein SynGap, a synaptic Ras-GTPase activating protein that binds to PSD-95, is one of the main substrates of CaMKII. CaMKII-induced SynGap phosphorylation activates MAPK signaling by stopping inactivation of Ras [96] Fig. (1) . AMPA receptors (preferentially the GluR1 subunit) are also substrates for CaMKII. CaMKII-mediated GluR1 phosphorylation potentiates AMPA receptor-mediated current and it is involved in the recruitment of AMPA receptors to the synapse from some intracellular pool, a mechanism most probably involved in LTP [49] [50] [51] [52] . Although CREB is another potential substrate for CaMKII, the nuclear enriched CaMKIV (which is activated by a Ca 2+ /calmodulin CaMKK) seems to be more involved in CREB phosphorylation Fig. (1). Work by Wu et al. suggests that CaMKIV and MAPK represent fast-sensitive and slow-sensitive convergent pathways, respectively, for activity-dependent CREB phosphorylation [93] . Altogether these signaling pathways suggest that mGlu 5 receptors can have an important role in the modulation of synaptic plasticity in the dendritic spines, which are believed to act as functional cellular compartments that constitute the main site of neuronal plasticity and longterm memory. In fact, stimulation of Group I mGlu receptors has been shown to induce morphological changes in the dendritic spines as well as to stimulate dendritic protein synthesis, chemical LTD and internalization of AMPA and NMDA receptors, and these processes seem to be interrelated [48, [97] [98] [99] [100] [101] [102] [103] (Fig. (1) ).
PKC activation seems to play a more important role in rapid agonist-induced mGlu 5 receptor desensitization than the homologous GRK-dependent desensitization [104] . Any manipulation that elevates PKC activity (or decreases the activity of serine/threonine phosphatases) is likely to result in a reduction of mGlu 5 receptor function. On the other hand, reductions of PKC activity (or increases in the activity of serine/threonine phosphatases) would result in an increased mGlu 5 receptor function [65, 104] . PKC-dependent homologous and heterologous desensitization may be important in regulating synaptic transmission and plasticity under normal conditions. It has been suggested that the oscillatory signaling of Group I mGlu receptors, which results in repetitive base-line oscillations in intracellular free Ca 2+ (with a frequency of 25-40 s for mGlu 5 receptors), might be related to repetitive cycles of PKC-dependent phosphorylation and dephosphorylation [91] . Although PKC inhibitors do not counteract Ca 2+ oscillations [105] , an enhancement of mGlu 5 receptor function by concomitant stimulation of NMDA receptors has been related to a reversal of a basal PKC-induced mGlu 5 receptor desensitization by NMDA receptor-mediated activation of protein phosphatases [65] . More recently, a similar mechanism has been thought to be involved in Group II mGlu receptor-mediated potentiation of the effects of Group I mGlu receptor activation. In this case, however, Group II mGlu receptor stimulation would counteract a PKAmediated mGluR 5 heterologous desensitization [106] . However, a role of PKA in mGlu 5 receptor desensitization is controversial, since other studies suggest that PKA activation increases mGlu 5 receptor function [79] .
PHYSIOLOGY OF ADENOSINE A 2A RECEPTORS
Extracellular adenosine depends mostly on the intracellular concentration of adenosine and nucleotides, such as ATP, AMP, cAMP [107] . In some brain areas, like the hippocampus, most of the extracellular adenosine seems to depend mostly on intracellular adenosine, the concentration of which depends on the rate of breakdown and synthesis of ATP [107] . Thus, adenosine is released as a neuromodulator [108] by the effector cells in response to an increased metabolic demand [109] . However, in the striatum, it has recently been suggested that the main source of extracellular adenosine is intracellular cAMP [110] , which is metabolized to AMP by means of phosphodiesterases and then to adenosine by the ectoenzyme 5'nucleotidase. Since cAMP can only be generated by the action of the enzyme adenylyl cyclase, striatal extracellular adenosine would mostly reflect an increased activation of receptors positively linked to adenylyl cyclase. The actions of adenosine are mediated by specific G protein receptors. From the four subtypes of adenosine receptors so far identified (A 1 , A 2A , A 2B and A 3 ) A 2A receptors are specially concentrated in the striatum [110] [111] , where they are mostly localized in the GABAergic striatopallidal neurons, colocalized with dopamine D 2 receptors (see below, and refs. [112, 113] . The recent ultrastructural analysis of the localization of A 2A receptors in the rat striatum show a very similar localization to that described for mGlu 5 receptors in primates [58] . That is, A 2A receptors are mostly localized postsynaptically in the dendrites and dendritic spines of the striatal GABAergic neurons. Importantly, A 2A receptor-immunoreactivity is observed primarily at glutamatergic (asymmetric) synapses [114] .
The major signal transduction pathway used by A 2A receptors depends on the activation of adenylyl cyclase, by means of G s -G olf coupling [115, 116] (see Fig. (2) . A 2A receptor mediated adenylyl cyclase activation generates cAMP, which activates a cAMP-dependent protein kinase (PKA), which in turn regulates the state of phosphorylation of various substrate proteins. One of those proteins, DARPP-32 (dopamine and cyclic adenosine 3', 5'-monophosphateregulated phophoprotein, 32 kDa) is expressed in very high concentration in the GABAergic efferent neurons [115, 116] . PKA-induced phosphorylation at a single site (Thr-34 of the rat sequence) converts DARPP-32 into a potent and selective inhibitor of protein phosphatase-1 (PP-1) [116] . Furthermore, DARPP-32 is, at another site (Thr-75), also phosphorylated under basal conditions, which converts it into an inhibitor of PKA [117] . PKA stimulates protein phosphatase-2A, which is the predominant phosphatase responsible for dephosphorylation of phospho-Thr-75-DARPP-32 [117] . It has been demonstrated that the removal of the inhibitory constraint on PKA by dephosphorylation of phospho-Thr-75-DARPP-32 provides a mechanism of amplification of the PKA signal transduction pathway [117] . Fisone and coworkers have demonstrated that in striatal slices stimulation of A 2A receptors produces phosphorylation of DARPP-32 at Thr-34 and dephosphorylation of DARPP-32 at Thr-75 [118] [119] [120] [121] (Fig. (2) ). CREB is another protein phosphorylated by PKA. Induction of cAMP liberates the catalytic subunits of PKA, which diffuse into the nucleus and induce cellular gene expression by phosphorylating CREB at a serine residue (Ser133) [122] . CREB activity declines after a couple of hours of continuous stimulation, due to dephosphorylation at Ser133 by PP-1 [122] . Thus, through PKA activation A 2A R stimulation in the GABAergic striatopallidal neurons can potentially produce a sustained increase in the transcription of some CREB modulated genes by a mechanism involving increased CREB phosphorylation and decreased CREB dephosphorylation (through phosphoThr-34-DARPP-32 mediated inhibition of PP-1 activity) Fig.  (2) . The immediate-early gene c-fos and the preproenkephalin and neurotensin genes are very well studied target genes the promoters of which contain consensus sites for CREB-P binding [123] [124] [125] [126] [127] . Recent studies have shown that A 2A receptor stimulation can, under certain conditions, increase the expression of c-fos (and other immediate-early genes), preproenkephalin and neurotensin genes (see below).
In addition to the preferential Gs(olf)-adenylyl cyclase pathway, A 2A receptors have also been shown to signal through PLC [128] , phosphatidylinositol 3-kinase (PI3K)-Akt [129] and MAPK [130] [131] [132] [133] [134] [135] pathways. Depending on the cellular system used A 2A -receptor mediated MAPK activation can be dependent on or independent of cAMP accumulation and PKA activation and, therefore, on the initial activation of the adenylyl cyclase pathway. Accumulation of cAMP and activation of MAPK have been shown to produce conflicting cellular responses, such as proliferation, growth arrest, apoptosis and differentiation, depending on the duration, strength of the external stimulus and cell type. These conflicting results seem to depend largely on the differential cross-talk between MAPK and cAMP/PKA and between MAPK and PI-3K/Akt signaling pathways in different situations [136, 137] . Instead of the Ras-Raf-1-MEK-ERK1-2 cascade, cAMP accumulation produces activation of another GTPase of the Ras family, Rap1, which leads to the sequential phosphorylation of the Raf isoform B-Raf, MEK and ERK1-2 [138] . Activation of Rap1 by cAMP might depend on both PKA-dependent andindependent mechanisms. PKA-induced phosphorylation of Src is required for PKA to activate Rap1 [139] and a family of cAMP-binding proteins termed cAMP-GEFs or Epacs seems to mediate PKA-independent activation of Rap1 [140, 141] . Although Rap1 can bind and activate B-Raf, it can also bind but inactivate Raf-1 (by blocking Ras binding to Raf-1 [138] ). Thus, the predominant Raf isoform seems to be the main determinant of the final effect of cAMP on MAPK activation. A predominance of B-Raf or Raf-1 will produce a cAMP-induced increase or decrease of MAPK activation, respectively [142] . Morice et al. found a predominant expression of B-Raf versus Raf-1 in the striatum, which was mostly localized in dendrites, which suggests that A 2A receptor-induced striatal stimulation of adenylyl cyclase might predominantly lead to MAPK activation [143] (Fig. (2) ). Nevertheless, A 2A receptor stimulation has been shown to produce MAPK activation by a Ras-dependent pathway in cells that did not express B-Raf (HEK 293 cells transfected with A 2A receptors; [131] ). As demonstrated in the same and other cell lines with the activation of transfected β 2 -adrenergic receptors, the mechanism for this Ras-dependent activation of MAPK seems to require Gβγ subunits and activation of Src (see above, and ref. [142] ). The differential activation of Src seems to determine the ability of of this non-receptor tyrosine kinase to activate MAPK through either Rap-1 (PKA-dependent phosphorylation) or Ras (PKA-nondependent phosphorylation) [142] . There is cross-talk between the MAPK and Akt signaling pathways, mostly due to inhibition of the MAPK signaling by Akt-induced phosphorylation of Raf-1 [136, 144] and the stimulation of PI3K by Ras [145] . The balance between Akt and MAPK signaling seems to depend mostly on the kind of agonist and the cellular background or stage of differentiation [136] . Finally, Lee et al. have shown that A 2A receptor stimulation causes PI3K activation by transactivation of Trk neurotrophin receptors by a Ca 2+ -and Src-dependent mechanism [129] (Fig. (2) ).
A rapid agonist-induced desensitization of A 2A receptors has been described in different cellular systems [146] [147] [148] [149] [150] [151] [152] [153] . This rapid desensitization involves A 2A receptor phosphorylation and, unlike mGlu 5 receptor desensitization (which mostly depends on PKC activation; see above), it is mostly dependent on GRK (homologous desensitization) (Palmer et al. 1994; Palmer and Stiles, 1997; 150,152-154) . Palmer and Stiles have identified the domain of the A 2A receptor specifically responsible for this desensitization in the proximal portion of the C-terminal segment (Thr-298) [154] . An unexpected additional finding of this work was an apparent functional redundancy of the long C-terminal segment of the A 2A receptor, distal to the mentioned domain. Removal of this region (95 amino acids) did not affect G protein coupling or the ability of the receptor to desensitize [154] . Selective activation of G proteins by stimulation of the A 2A receptor is predominantly dictated by its 3IL (in its N-terminal portion) [155] . The C-terminal segment seems to be required for the transition of the A 2A receptor to the activated state, since its truncation blunts constitutive activity [135] . Finally, the C-teminal segment of the A 2A receptor seems to be involved in the formation of A 2A -D 2 heteromeric complexes and to the interaction of A 2A receptor with the actin cytoskeleton (see below). A longer agonist exposure induces receptor internalization, which has been shown to be a necessary step for either resensitization or down-regulation of A 2A receptor through clathrin-coated vesicles [150, 152] .
PHYSIOLOGY OF DOPAMINE D 2 RECEPTORS
The striatum receives the most dense dopamine innervation and contains the highest concentration of dopamine receptors in the brain [156] . [157] . Recent studies suggest that the N-terminal portion of the 3IL of the D 2 receptor is involved in interactions with actin cytoskeleton-binding proteins (see below). Finally, our results suggest that two strings of basic residues of the 3IL of the D 2 receptor establish coulombic interactions with some acidic residues of the distal part of the C-terminal segment of the A 2A receptor (in preparation). One string of basic amino acids of the D 2 receptor is also located in the N-terminal portion of the 3IL, while the other string is located in the middle portion of the 3IL of only the D 2L (amino acids missing in the D 2S ). These interactions are most probably involved in the formation of A 2A -D 2 heteromeric receptor complexes (see below). Although these two isoforms of D 2 receptors may be differentially phosphorylated and can display differential G protein interactions [162] [163] [164] , no clear functional differences have been found on signaling. More clear-cut differences have been found, however, on intracellular trafficking. First, the processing to the mature receptor differs between the two isoforms. The D 2S receptor is processed faster than the D 2L receptor and a significant portion of D 2L receptor remains in its partially processed form in an intracellular compartment and does not reach the plasma membrane [165] . More relevant from a therapeutic and patho-physiological point of view is the differential response of D 2L and D 2S to prolonged exposure to agonists (see below and ref. [166] ). In some cell systems both isoforms have been shown to internalize upon agonist exposure by a GRK-β-arrestin dependent mechanism [18, 167] . However, the degree of internalization of D 2S was greater than for D 2L receptors [167] . In fact, in other cell systems, D 2L receptors have been found to even up-regulate in response to agonist pretreatment [168] [169] [170] [171] , which seemed to be related to agonist-induced translocation to the membrane of existing intracellular receptors and to de novo receptor synthesis [171] . According to Ng et al. [171] this up-regulation might underlie the reported resistance (or slow onset) of D 2L receptors to desensitization [37, [168] [169] [170] [171] The dopamine D 2 receptor (both D 2L and D 2S ) has been shown to signal through multiple pathways when studied in different cell systems [157] (Fig. (3) ). It becomes a challenge, therefore, to determine the main signaling pathways utilized by D 2 receptors in the central nervous system. It was initially thought that inhibition of adenylyl cyclase was the main functional consequence upon agonistinduced activation of D 2 receptors (reviewed in ref. [157] ). In fact, this seems to be the predominant D 2 receptor signaling in the striatum. Strong impairment of D 2 receptor function is observed after the genetic inactivation of either PKA or of type 5 adenylyl cyclase (AC5) [175, 176] , the main adenylyl cyclase isoform found in the striatum [176, 177] . In each case there is a loss of the biochemical and behavioral effects of D 2 receptor antagonists [175, 176] . D 2 receptor-mediated adenylate cyclase inhibition has also been shown in other cellular systems and seems to be dependent on the coupling of the receptor to Gi proteins [178, 179] . Supression of Ca 2+ currents through L-type voltage dependent Ca 2+ channels (L-type VDCCs) is one of the best established adenylyl cyclase-independent signaling pathways of D 2 receptors demonstrated in cell lines, lactotroph cells and striatal neurons [179] [180] [181] . This pathway seems to involve Go, βγ units, PLC activation, IP3 dependentintracellular Ca 2+ mobilization and activation of the Ca 2+ -dependent serine-threonine phosphatase calcineurin (PP-2A) [180, 181] (Fig. ( 3) ). Calcineurin has not only been shown to reduce L-type VDCC currents in different cell preparations [181] , but to be a main phosphatase involved in dephosphorylation of DARPP-32 (at Thr-34; see above). D 2 receptor activation produces DARPP-32 dephosphorylation both by inhibiting adenylyl cyclase activity and by a Ca 2+ /calcineurin-dependent and adenylyl cyclaseindependent mechanism [182] (Fig. (3) ). D 2 receptor stimulation has been shown to activate MAPK in different cell lines [179, [183] [184] [185] , in brain slices [186] and in striatal primary cultures [187] . CaMK, PKC, DARPP-32 and elevated Ca 2+ seem to be important components of the D 2 receptor-mediated signaling involved in MAPK activation [186] . Interestingly, MAPK activation can only be produced in the dopamine-denervated striatum [188] . Furthermore, MAPK activation might be involved in the sensitized locomotor response to D 2 receptor stimulation in unilateral 6-hydroxydopamine-lesioned rats [188] . However, recent studies have shown that D 2 receptor agonists specifically inhibit the activation of MAPK in the striatopallidal neurons induced by corticostriatal afferent stimulation [189] . According to these studies, the previously reported D 2 receptor agonist-induced MAPK activation in the dopamine-denervated striatum [188] seems to be only induced in striatal interneurons [189] . On the other hand, D 2 receptor antagonist treatment results in a strong and selective MAPK activation in striatopallidal neurons [189] . The same inhibitory effect of D 2 receptor agonists has been observed in pituitary cells and in the prolactin-secreting pituitary cell line GH4ZR7, where the D 2 receptor-mediated inhibitory modulation of MAPK activation has recently been characterized [180, 190] . In these cells, both adenylyl cyclase-dependent and independent mechanisms for the D 2 -receptor mediated inhibition of MAPK activation were found and D 2 receptor stimulation not only antagonized stimulatory effects of exogenous hormones (e.g. TRH) on MAPK, but also suppressed basal levels of activated MAPK. Rap 1 inactivation could be an additional mechanism by which D 2 receptor activation counteract an adenylyl cyclase-dependent inhibition of MAPK [180] . This would be related to the demonstrated direct interaction between Go (the Gαο subunit) and a Rap1 GTPase-activating protein (Rap1GAP), which results in the sequestration of Rap1GAP and the consequent increase in activated Rap1. On the other hand, activation of Go would lead to the release of Rap1GAP with the consequent Rap1 inactivation [191] (Fig. (3) ). Inhibition of Ca 2+ influx through L-type VDCCs and activation of a phosphotyrosine phosphatase have been proposed as possible mechanisms involved in the adenylyl cyclase-independent D 2 receptor-mediated inhibition of MAPK activation [180, 190] . L-type VDCCs play a key role in conveying information from the membrane (neuronal activation) to the nucleus (neuronal plasticity) [192] . Furthermore, this signaling involves the formation of an L-type VDCC/calmodulin complex and the consequent activation of MAPK [192] . Therefore, in the striatopallidal neuron, the D 2 receptor-mediated modulation of L-type VDCC currents [181] might be the main mechanism involved in the adenylyl cyclase-independent D 2 receptor-mediated inhibition of MAPK activation (Fig. (3) ).
HOMO-AND HETEROMERIZATION OF GLUTA-MATE mGLU 5 , DOPAMINE D 2 AND ADENOSINE A 2A RECEPTORS
In recent years an increasing number of biochemical (non-denaturing SDS-PAGE, coimmunoprecipitation and biotinylation) and biophysical (FRET, Fluorescence Resonance Energy Transfer, and BRET, Bioluminiscence Resonance Energy Transfer) techniques have revealed the existence of GPCR homo-and heteromerization. Early studies suggested that GPCRs could be present as dimers in the plasma membrane. To date several GPCRs, including the β-adrenergic receptor [193] , the δ-opioid receptor [194] , the adenosine A 1 receptor [195] , the mGlu 5 receptor [196, 197] and the dopamine D 2 receptor [166, 198] have been shown to form dimers in native tissues or when expressed in mammalian cells. Dimerization of the β-adrenergic receptor is important for efficient receptor-G protein coupling [193] , whereas for the opioid receptor dimerization seems to have a role in the regulation of receptor internalization [194] . Similarly, different domains of the proteins appear to be responsible for the interaction of the different receptors.
For mGlu 5 receptors there is good evidence that the Nterminal domain plus the first transmembrane domain play a key role in the formation of homodimers, suggesting that determinants within these domains are responsible for the interaction of the receptor molecules [196] . Indeed, cysteine residues present within the N-terminal domain are responsible for the disulphide bonding of the dimers [196, 197] . Other members of the mGlu receptor family do not form heteromers, even if they belong to the same mGlu receptor group, such as mGlu 1a and mGlu 5 receptors [196, 197] . Furthermore, these receptors do not form heteromers with their different C-terminal tail splice variants, such as mGlu 1a and mGlu 1b receptors [199] . The existence of dimeric forms of the D 2 receptor was initially shown by means of biochemical techniques. These observations were based on the fact that several homomers are resistant to the denaturation properties of SDS. Thus, it was possible early on by Ng and colleagues to show that the D 2 receptor expressed in cell lines formed molecular species not only corresponding to monomers but also dimers [166, 200] [201] ). When we isolated the membrane A 2A receptor by cell surface protein biotinylation, using a membrane impermeable biotin-ester and streptavidin-agarose affinity precipitation of the membrane proteins, we could demonstrate that the receptor was present as a dimer in the plasma membrane (in preparation).
Gouldson et al. hypothesized that domain swapping with involvement of transmembrane regions 5 and 6 is involved in homodimerization of β 2 adrenergic receptors [202] . Peptides corresponding to transmembrane region 6 of the β 2 adrenergic receptor were found to disrupt the dimerization as well as receptor activation, indicating a participation of the hydrophobic forces in the transmembrane region 6 in the dimerization interface. Also, agonist stimulation was found to stabilize the dimeric state of the receptor, while inverse agonists favored the monomeric species; this suggests that interconversion between monomeric and dimeric forms may be important for biological activity [193] . Similarly, peptides corresponding to the D 2 receptor transmembrane regions 6 and 7 dissociated the D 2 receptor dimer. Such peptide actions on the dimer were receptor-and region-specific. Interestingly, ligands did not bind to peptide-dissociated D 2 receptors and D 2 receptor dimers also dissociated as a function of increasing temperature and in the presence of acid environment [200] . Thus, for some GPCRs, such as β 2 adrenergic and D 2 receptors, homodimerization seems to involve specific intermolecular, noncovalent, electrostatic interactions of residues within the transmembrane α−helices. In this model the receptor dimer is rearranged in a much more stable conformation favored by the interaction of the hydrophobic interfaces [203] .
The existence of GPCR heteromers was first postulated in 1993 by Zoli et al. [204] to provide a molecular explanation to the large amount of evidence obtained on the intramembrane and functional receptor-receptor interactions between GPCRs. Since then, the existence of heteromers of several GPCRs has been reported (see ref. [2] 5 receptors are physically associated by means of direct protein-protein interactions (true heterodimers) or they are linked via additional cytosolic proteins. Thus, interactions of the receptors' cytoplasmic C-termini or intracellular loops with specific targeting proteins provide an alternative mechanism for GPCR heteromerization. The best example is the coupling of NMDA with Group I mGlu receptors by means of PSD-95-Shank-GKAP protein complexes (see above). Furthemore, through these interactions NMDA and Group I mGlu receptors are connected to the cytoskeleton, since Shank also binds to cortactin, which directly interacts with actin [60] . Also, filamin-A, a member of the α-actinin/spectrin/dystrophin family of actin-binding proteins has recently been identified as a binding partner of mGlu 5 receptors. Filamin-A is a ubiquitously expressed dimeric actin-cross-linking phosphoprotein that promotes orthogonal branching of actin filaments, contributing to the formation of the actin meshwork adjacent to the surface cell membrane and linking membrane glycoproteins to the actin cytoskeleton [205] . Several dopamine D 2 receptorinteracting proteins, including filamin-A, have been identified. It is the N-terminal portion of the 3IL of the D 2 receptor that interacts with filamin-A [206] . This interaction, like that for the mGlu 5 receptor, may be important for establishing the correct subcellular localization of D 2 receptor. Similarly, it has been demonstrated that the Nterminal portion of the 3IL of the D 2 receptor also interacts with protein 4.1N [207] , a recently identified member of the 4.1 family of cytoskeletal-associated proteins that is specifically enriched in neurons. The 4.1 proteins are critical components of the spectrin/actin cytoskeleton and provide attachement between cytoskeleton and the cell membranes. Protein 4.1N has been shown to directly interact with the GluR1 subunit of the AMPA receptor and to colocalize with AMPA receptors at excitatory synapses [208] . It is suggested that protein 4.1N-D 2 receptor interaction is required for localization or stability of dopamine receptors at the neuronal plasma membrane [207] . Spinophilin, a recently characterized F-actin and PP-1-binding protein with a single PDZ domain is also a protein that interacts with the 3IL of D 2 receptor [209] . It has been suggested that spinophilin might also be important for linking D 2 receptors to downstream signaling molecules and the actin cytoskeleton [209] . Currently and by similar approaches we are searching proteins that interact directly with the C-terminal tail of the A 2A receptor. An actin binding protein, actinin, is a potential partner of the A 2A receptor C-terminal tail. Actinin, like filamin-A, is an actin crosslinking protein that shares similar properties including the formation of antiparallel homodimers (Burgueno et al., in preparation). In conclusion, the actin cytoskeleton may serve as a platform for assembling GPCRs in specific plasma membrane domains and also may participate in stabilizing direct interactions between these receptors necesaries for the formation of homo-and heteromers of GPCRs. It is important to note that the Homer-Shank-actin cytoskeleton interaction involves a linkage of mGlu receptors, and potentially adenosine and dopamine receptors, with the NMDA receptor scaffold. Thus, the Homer-Shank-actin cytoskeleton interaction could be of special importance in processes of synapse formation and plasticity, where the docking of mGlu, adenosine and dopamine receptors to a pre-established NMDA receptorassociated PSD-95 complex could play a critical role (see above). On the other hand, this physical association between NMDA, mGlu, adenosine and dopamine receptors could be important in the fine tuning of glutamate-adenosinedopamine cross-talk which is described below (see also Fig.  (4) ).
GLUTAMATE mGLU 5 -ADENOSINE A 2A -DOPAMINE D 2 RECEPTOR INTERACTIONS IN THE STRIATUM. IMPLICATIONS FOR DRUG THERAPY IN NEURO-PSYCHIATRIC DISORDERS
The basic intrastriatal circuitry is quite simple, since GABAergic projection neurons, constitute more that 90% of the striatal neuronal population. The GABAergic projection neurons mainly convey information carried by glutamatergic cells located in cortical and limbic areas, like the amygdala and hippocampus, and by dopaminergic mesencephalic cells, which are located in the substantia nigra and ventral tegmental area, and [210, 211] . There are two subtypes of striatal GABAergic efferent neurons, the striatopallidal and strioentopeduncular neurons. As mentioned before, adenosine A 2A and dopamine D 2 (D 2L ) receptors are colocalized in the striatopallidal GABAergic neurons, which also contain the peptide enkephalin. The other subtype of striatal GABAergic efferent neurons, the striatoento- peduncular GABAergic neurons, contain the peptides dynorphin and substance P and dopamine receptors predominantly of the D 1 subtype (reviewed in ref. [6] ). Striatal mGlu 5 receptors are mostly localized in the striatal GABAergic efferent neurons, but without an obvious preference for either the striatopallidal or the striatoentopeduncular subtypes . In any case, a distinct colocalization of mGlu 5 , A 2A and D 2 receptors exists in the dendritic spines of the striatopallidal neurons (see above and ref. [2] ). Stimulation of the striatoentopeduncular GABAergic neurons results in motor activation and stimulation of the striatopallidal neurons produces motor inhibition. Dopamine, or dopamine agonists, will induce motor activation by activating the striatoentopeduncular neurons (acting on stimulatory D 1 receptors) and by depressing the striatopallidal neurons (acting on inhibitory D 2 receptors) [211, 215] . In Parkinson's disease a preferential degeneration of the nigrostriatal dopaminergic system produces striatal dopamine depletion with the consequent impairment of the functioning of these circuits, which is associated with hypokinesia. Hyperactivity of the GABAergic striatopallidal neurons due to the release from the strong D 2 receptor mediated tonic inhibitory effects of endogenous dopamine is probably the main pathophysiological mechanism responsible for this hypokinesia [216] .
The GABAergic striatopallidal neurons that originate in the ventral part of the striatum, the nucleus accumbens (NAc), play a key role in the conversion of motivation into action via transfer of information from the limbic to the motor system (for review, see ref. [5] ). In fact, it is a final common pathway for opiate and psychostimulant mediated reward [217] and a common target for antipsychotic drugs [5] . Thus, blockade of D 2 receptors in the ventral GABAergic striatopallidal neurons seems to be involved with the antipsychotic effects of neuroleptics or, at least, with their therapeutic effect on the positive symptoms of schizophrenia. On the other hand, blockade of D 2 receptors in the dorsal GABAergic striatopallidal neuron is associated with the extrapyramidal side effects of neuroleptics, such as parkinsonism. One of the possible properties of atypical neuroleptics, which have a decreased liability of those side effects, is a preferential D 2 receptor blockade in the ventral striatum (see below).
The formation of receptor complexes modifies the single receptor transducing characteristics and leads to the appearance of "emergent properties" [218] . The study of glutamate mGlu 5 5 receptor interactions. At the biochemical level, by using membrane preparations of rat striatum or of cell lines expressing the corresponding receptors, and by using receptor autoradiography in rat and human striatal sections, it has been shown that stimulation of A 2A receptors decreases the affinity of D 2 receptors for dopamine or dopamine agonists [115, [219] [220] [221] [222] [223] [224] [225] [226] . Also, in membrane preparations from rat striatum, non-selective stimulation of Group I mGlu receptors or selective stimulation of mGlu 5 receptors decreased the affinity of D 2 receptors for dopamine [221, 227, 228] . Finally, costimulation of A 2A receptors and Group I mGlu receptors or mGlu 5 receptors exerts a synergistic effect on the modulation of the binding characteristics of D 2 receptors [221, 227, 228] .
In addition to the intramembrane receptor-receptor interactions, the existence of A 2A -D 2 and A 2A -mGlu 5 heteromeric receptor complexes provides the possibility for close cross talk between A 2A , D 2 and mGlu 5 receptors (Fig. (4) ). A strong antagonistic interaction between A 2A receptors and D 2 receptors at the adenylyl cyclase level has been demonstrated in different cell lines [37, 115] . In CHO cells stably cotransfected with A 2A and D 2 receptor cDNAs, stimulation of A 2A receptors produced a strong stimulation of cAMP, CREB phosphorylation and increased c-fos expression [115] . A selective D 2 receptor agonist dose-dependently counteracts these effects and a complete blockade is attained at low concentrations of the D 2 receptor agonist [115] . Similarly, in striatal slices a D 2 receptor agonist completely counteracts Thr-34 phosphorylation of DARPP-32 by A 2A receptor stimulation [120] . Striatal D 2 receptors are tonically stimulated by basal endogenous levels of dopamine, and many experimental results indicate that this tonic D 2 receptor stimulation strongly counteracts the tonic A 2A receptor stimulation induced by the basal striatal levels of adenosine. . On the other hand, the biochemical effects related to adenylyl cyclase activation, which are only clearly apparent with the removal of the D 2 receptor-mediated inhibitory tone, do not seem to play a major role in some functional and behavioral effects produced by the administration of A 2A receptor agonists and antagonists. For instance, the systemic administration of a low dose of a selective A 2A receptor agonist produces a pronounced motor depression (already shown to be centrally mediated; see ref. [241] ) and selectively counteracts D 2 receptor agonist mediated behaviours [242, 243] without inducing an increased c-fos striatal expression [133, 230, 233] . In fact, AC5 knockout mice (see above) have a loss of A 2A and D 2 receptor-mediated adenylyl-cyclase signaling, loss of behavioral effects of D 2 receptor antagonists and preservation of the motor depression induced by A 2A receptor agonists [176] . Most probably the adenylyl cyclase-independent behavioral effects of A 2A receptor agonists are dependent on adenylyl cyclase-independent signaling pathways (see above) or to the reciprocal antagonistic A 2A -D 2 receptor intramembrane interaction, which could be more effective at modulating other D 2 receptor-mediated signaling pathways, such as the decrease in L-type VDCC currents (see above) ( Fig. (4) ).
As mentioned above, the systemic administration of A 2A receptor antagonists counteracts most of the biochemical (see above) as well as the motor depressant and cataleptic effects secondary to the genetic inactivation or pharmacological interruption of D 2 receptor mediated neurotransmission. This has been repeatedly demonstrated in a number of experimental models involving rodents pretreated with D 2 receptor antagonists, reserpine or MPTP or after genetic inactivation of D 2 receptors [231, 237, 238, [244] [245] [246] [247] [248] [249] [250] or involving MPTP-treated monkeys [251, 252] . These experiments suggest that A 2A receptor antagonists might be useful in the treatment of Parkinson's disease. However, although it has been claimed that A 2A receptor antagonists might be devoid of the secondary dyskinetic effects associated with treatment with dopamine agonists [251, 252] , it is still a matter of debate as to whether they could be used alone or if they would be more efficacious when combined with D 2 receptor agonists [248] . In fact, in another classical experimental model of Parkinson's disease, the rat with a unilateral lesion of the nigrostriatal pathway [253] , A 2A receptor antagonists do not produce the behaviour that predicts antiparkinsonian activity: turning behavior away from the lesioned side [248, 254, 255] . Nevertheless, in all animal models of Parkinson's disease thus far tested (reserpinized mice, rats with unilateral 6-OH-dopamine lesions, MPTP-treated monkeys) A 2A receptor antagonists strongly potentiate the motor activation induced by D 2 receptor agonists [228, 248, 252, [255] [256] [257] [258] [259] . Importantly, cotreatment with A 2A receptor antagonists and L-DOPA does not increase the non-wanted dyskinetic effects in MPTPtreated monkeys [252, 257] . Finally, recent electrophysiological experiments in the rat dopamine denervated striatum showed that the infusion of an A 2A receptor antagonist does not produce any effect on its own, but strongly potentiates the D 2 receptor agonist-induced inhibition of striatal neuronal activity [255] [239] . On the other hand, decreased striatal dopamine release and decreased psychostimulant-induced motor activation (functional striatal hypodopaminergic activity) has been found in mice lacking A 2A receptors [240, 260] .
We are beginning to understand the physiological conditions (where there is no interruption of D 2 receptor mediated neurotransmission) that allow A 2A receptor stimulation to produce a clear adenylyl cyclase activation, with the corresponding increase in phospho-Thr-34-DARPP-32 and CREB phosphorylation and increases in the expression of c-fos and the preproenkephalin and neurotensin genes. One such condition seems to be mGlu 5 receptor co-activation [133] . In HEK-293 cells transiently transfected with A 2A and mGlu 5 receptors stimulation of A 2A receptors produced an increase in cAMP levels that was not significantly modified by the concomitant stimulation of mGlu 5 receptors [133] . Stimulation of either mGlu 5 [133] . Nevertheless, there is a strong functional synergistic A 2A -mGlu 5 receptor interaction on MAPK and on c-fos expression. Importantly, the effect on c-fos expression was counteracted by incubation with the MEK inhibitor PD98059 [133] . A significant c-fos induction is also obtained in the rat striatum, preferentially in the NAc, after the concomitant central administration of A 2A and mGlu 5 receptor agonists, which is ineffective when they are administered alone [133] . MAPK seems, therefore, to be a main biochemical integration element responsible for the synergistic interactions between A 2A and mGlu 5 receptors (Fig. (4) ). Alternatively. There might be levels of interaction upstream from MAPK, such as non-receptor tyrosine kinases or other enzymes recently demonstrated to be activated by GPCRs through G protein-independent signaling (see above). In any case, concomitant stimulation of A 2A and mGlu 5 receptors seems to allow A 2A receptor stimulation to overcome the tonic inhibitory effect of dopamine and induce striatal c-fos expression. We favor the idea that this mechanism can take place under conditions of intense glutamatergic neurotransmission, which is known to induce adenosine release, most probably due to the neuronal metabolic demand imposed by the increased excitatory input [107, 109] . This is also consistent with previous studies showing that corticostriatal stimulation produces selective MAPK activation and induction of immediate early genes in the striatopallidal neurons [189, 261, 262] . That MAPK activation is responsible for the striatal induction of immediate early genes after corticostriatal stimulation is supported by the reported counteracting effects of MEK inhibitors [263] .
The role of mGlu 5 receptors and their interactions with A 2A and D 2 receptors in animal models of Parkinson's disease is beginning to be evaluated. In unilaterally 6-OHdopamine-lesioned rats, the intracerebral administration of a selective mGlu 5 receptor agonist selectively inhibits the contralateral turning induced by a D 2 receptor agonist [228] . The effect of the mGlu 5 agonist is potentiated by an A 2A receptor agonist and attenuated by an A 2A receptor antagonist [228] . These results suggest that mGlu 5 receptor antagonists, alone or in combination with A 2A receptor antagonists or D 2 receptor agonists or both, might provide a new therapeutic approach for basal ganglia disorders, such as Parkinson's disease. In fact, some studies have recently shown antiparkinsonian-like effects of mGlu 5 antagonists in rats [264] .
Preferential blockade of D 2 receptors in the ventral striatum (with relative sparing of D 2 receptors in the dorsal striatum) is one of the main factors responsible for the atypical profile of an antipsychotic. Typical antipsychotics, like haloperidol, increase c-fos expression in the dorsal and ventral striatum, while atypical antipsychotics, like clozapine, selectively elevates c-fos expression in the ventral striatum, and specially in the shell of the nucleus accumbens [234, [265] [266] [267] . A similar differential response to haloperidol and clozapine has also been demonstrated for the striatal expression of neurotensin [267] . It has also been shown that the increased c-fos expression in the ventral striatum induced by both haloperidol and clozapine selectively takes place in the ventral GABAergic striatopallidal neuron [268] and that it can be counteracted by the systemic administration of an A 2A receptor antagonist [234] . These results raise the possibility that A 2A receptors might be involved in the mediation of the antipsychotic effects of neuroleptics. The D 2 , A 2A and mGlu 5 receptor-mediated modulation of GABAergic neurotransmission in the ventral striatopallidal neurons has been studied with the dual-probe in vivo microdialysis technique [220, 269] . The perfusion of a D 2 receptor antagonist, an A 2A receptor agonist or a mGlu 5 receptor agonist in the NAc increases GABA levels in the ipsilateral ventral pallidum [220, 269] . Co-perfusion of A 2A receptor agonist and D 2 receptor antagonist or co-perfusion of A 2A and mGlu 5 receptor agonists produces synergistic increases in pallidal GABA [220, 269] . Finally, a D 2 receptor agonist completely counteracts the effect of the A 2A receptor agonist and partially counteracts the effect of A 2A plus mGlu 5 receptor agonists [269] . From these results, we have suggested a possible use of A 2A receptor agonists as antipsychotic drugs, alone or in combination with D 2 receptor antagonists, which could imply a reduction in the secondary effects of the already established antipsychotic [220] . In fact, the systemic administration of an A 2A receptor agonist gives the pharmacological profile of an atypical antipsychotic in several animal models [242, 243, 270] . Another possible therapetic approach is the use of mGlu 5 receptor agonists, alone or in combination with A 2A receptor agonists, D 2 receptor antagonists, or the combination of the two.
GLUTAMATE mGLU 5 -ADENOSINE A 2A -DOPAMINE D 2 RECEPTOR INTERACTIONS IN THE STRIATUM. IMPLICATIONS FOR NEURO-ALTERATIONS IN DRUG USE AND ABUSE
An important variable when targeting GPCRs in drug therapy is the possible receptor adaptations due to long exposure to agonists. A clear example is the potential application of A 2A receptor agonists in hypertension. A 2A receptors are present in the cardiovascular system and their stimulation induces hypotension [271, 272] . Continuous administration of an A 2A receptor agonist causes rapid and complete tolerance to the drug's hypotensive effects trough downregulation of A2A receptors [273] . Tolerance may limit the potential use of A 2A agonists not only in hypertension, but also in schizophrenia (see above and ref. [5] ). As summarized above, D 2 receptors are established targets for drug therapy in the treatment of neuro-psychiatric disorders, such as Parkinson's disease and schizoprenia. It was already mentioned that in cell lines the D 2L receptor isoform is resistant to desensitization and that long-term agonist exposure is associated with up-regulation of D 2L receptors. On the other hand the D 2S isoform always down-regulates and shows faster and stronger desensitization (see above and refs. [168] [169] [170] [171] . It was also mentioned that striatal D 2L receptors are localized postsynaptically, mainly in the GABAergic striatopallidal neurons; therefore, they are the ones colocalized with A 2A receptors. D 2S receptors are presynaptic D 2 receptors localized mainly in the dopaminergic cells [172] [173] [174] . Thus, now it remains to be established which are the adaptations of both D 2 receptor isoforms that take place in the brain with long-term agonist exposure.
There are already experimental data which support that the D 2 autoreceptors (D 2S receptors) localized in dopaminergic cells are very sensitive to down-regulation upon exposure to selective D 2 receptor agonists [274] [275] [276] or to indirect dopamine agonists, such as the psychostimulants cocaine or amphetamine. Thus, repeated cocaine or amphetamine administration is associated to subsensitivity of both axonal and somatodendritic D 2 autoreceptors (reviewed in ref. [277] ). D 2 autoreceptors exert an inhibitory effect on firing, dopamine synthesis and dopamine release of dopaminergic cells [274] [275] [276] and they seem to play a crucial role in mediating the autoinhibition observed in conditions of high extracellular dopamine concentration, such as those obtained with the administration of psychostimulants [278] . D 2 autoreceptor subsensitivity seems to be the main mechanism involved in the increase in dopamine release induced by repeated administration of psychostimulants [277] and seems to involve a reduction in Gi and Go levels [279] in addition to receptor down-regulation. Behavioral sensitization to psychostimulants makes reference to the increased motor stimulant effects to these drugs upon subsequent exposure. Core features of this sensitization are its long-lasting quality, with long-lasting or irreversible neurobiological alterations [280] , cross-sensitization between different psychostimulants and environmental stressors [281, 282] and faster development in a novel environment [283] . Although in behavioral sensitization to psychostimulants a good correlation exists between motor activation and striatal dopamine release, mechanisms other than D 2 autoreceptor subsensitivity seem to be involved, which also vary among different psychostimulants [277] . Nevertheless, all mechanisms involved in behavioral sensitization seem to result from time-dependent neuroalterations within the circuitry that includes the dopaminergic cells that innervate the nucleus accumbens. In fact, evidence also exists for an increased sensitivity of postsynaptic D 2 receptors to agonists with repeated administration of cocaine and heroin [284] . These effects seem to be especially salient during the early phases of drug withdrawal [284] , a period during which releasability of dopamine is often diminished or unaffected [277] . The period of behavioral sensitization of D 2 agonists is also associated to D 2 receptor agonist-mediated relapse to cocaine-and heroin-seeking behaviour [284] . These results suggest that the increased sensitivity of D 2 receptors (most probably D 2L ) to agonists induced by drugs of abuse may play a permissive role in drug-induced relapse behavior. In fact, stimulation of D 2 receptors (but not D 3 or D 1 receptors) appears to be necessary for induction of relapse to cocaineseeking behaviour in non-human primates [285] .
Psychostimulant-induced psychosis in humans has been suggested to be related to behavioral sensitization to psychostimulants in animals (for review, see ref. [286] ). Subjects who experience methamphetamine psychosis when chronic abusers remain vulnerable to methamphetamineinduced psychosis even after years of withdrawal [287] . In these subjects a low dose of methamphetamine or a stressful event can produce a recurrence of a psychotic episode [288] . Furthermore, an "endogenous" sensitization to psychostimulants has also been demonstrated in schizophrenic patients (reviewed in ref. [286] ) and brain imaging studies have shown evidence for increased amphetamine-induced striatal dopamine release in schizophrenia [289, 290] . Therefore, similar patho-physiological mechanisms might take place in psychostimulant-induced psychosis and in schizophrenia, which could share some of the neuroalterations associated with behavioral sensitization to psychostimulants in animals. Laruelle [286] suggests that a common mechanism leading to these neuro-alterations is an initial period of excess dopaminergic transmission, which leaves long-lasting alterations in the brain. One main alteration is a sensitization of the dopaminergic systems, which might depend on both pre-and post-synaptic changes in D 2 receptors, such as subsensitivity of D 2 autoreceptors (D 2S ) and supersensitivity of post-synaptic D 2 receptors (D 2L ) to agonists (or endogenous dopamine). In schizophrenia, it is suggested that the initial period could be related to a dysregulation of dopaminergic neurons of the ventral tegmental area, most probably involving their glutamatergic afferents from the prefrontal cortex. Thus, these glutamatergic neurons are hypothesized to exert an important role in the induction of sensitization to psychostimulants [291, 292] . Furthermore, a neonatal lesion of the medial temporal lobe, a process that mimics some neurodevelopmental changes of the schizophrenic brain [293] , disrupts the prefrontal cortical regulation of striatal dopamine [294] .
One more pathological state to be considered as a manifestation of sensitization to the effects of dopaminergic agonists is the L-DOPA-induced motor response complications of patients with Parkinson's disease and, in particular L-DOPA-induced dyskinesia. Striatal dopamine denervation and intermittent or pulsatile dopamine-receptor stimulation seem to be the two main conditions necessary for the development of L-DOPA-induced dyskinesia [295, 296] . It is very well established that dopamine denervation leads to an increased sensitivity of striatal dopamine receptors to the effects of agonists [253] . Both post-synaptic D 1 and D 2 receptors are involved and D 2 receptor supersensitivity seems to be mediated by both receptor upregulation and enhanced coupling to G proteins [297] [298] [299] [300] . Similarly, in untreated parkinsonian patients most studies suggest that there is an upregulation of D 2 receptors (see, for instance, refs. [301, 302] ). Some experimental findings in the unilateral 6-OH-dopamine-lesioned rat indicate that chronic treatment with high doses of L-DOPA can only produce a partial recovery of the denervation-induced supersensitivity of striatal post-synaptic receptors to agonists [303] . In agreement, in unilateral 6-OH-dopamine-lesioned rats, high doses of L-DOPA do not affect enkephalin levels or preproenkephalin mRNA in striopallidal GABAergic neurons [304, 305] . This demonstrates the existence of the previously hypothesized irreversibility of denervationinduced supersensitivity of striatal dopaminergic receptors [303] , which might be related to the resistance of postsynaptic D 2 receptors (D 2L ) to down-regulation. Also in rats with unilateral striatal dopamine denervation, lower doses or intermittent L-DOPA treatment induces behavioral sensitization (turning behavior and abnormal involuntary movements [AIM]), with increased turning behaviour induced by L-DOPA and with cross-sensitization to apormorphine or to the D 2 receptor agonist bromocriptine [306] [307] [308] [309] [310] . The analysis of apomorphine-induced c-fos expression in the denervated striatum and ipsilateral globus pallidus [309] strongly suggests that L-DOPA pre-treatment increases and decreases the denervation-induced sensitization of D 2 and D 1 receptors, respectively, as previously postulated [306] . Thus, an increased sensitivity of the D 2 receptor-containing striatopallidal GABAergic neurons play an important role in the development of L-DOPA-induced dyskinesia. However, the role of the D 1 receptor-containing striatoentopeduncular GABAergic neurons cannot be understimated. Phenotypical changes of these neurons, including increased expression of prodynorphin mRNA and D 3 receptor upregulation, have also been demonstrated in animal models of Parkinson's disease treated with L-DOPA [305, 311, 312] . In fact, similar changes have also been suggested to be involved in sensitization to psychostimulants (reviewed in ref. [312] ). Altogheter, the above-mentioned findings allow us to postulate the following working hypothesis: an increased sensitivity of D 2L receptors to agonists in the striatopallidal neurons is a common patho-physiological mechanim involved in sensitization to psychostimulants and L-DOPAinduced dyskinesias. As described before, we recently found evidence for co-aggregation, co-internalization and codesensitization of both A 2A and D 2L receptors upon agonist exposure [37] . Importantly, under our experimental conditions, D 2L receptor stimulation was only associated to significant desensitization upon concomitant stimulation of A 2A receptors [37] . Co-stimulation of A 2A and D 2 receptors, by inducing desensitization of D 2L receptors could be of therapeutic use in sensitization to psychostimulants and L-DOPA-induced dyskinesias. In fact, evidence in favor of this hypothesis has already obtained in animal models. Shimazoe et al. found that A 2A but not A 1 receptor agonists avoid the development of methamphetamine-induced sensitization [313] . Similarly, we have found that A 2A receptor agonist cotreatment avoids the development, but not the expression of L-DOPA-induced behavioral sensitization (turning and AIM) in rats with unilateral striatal dopamine denervation (in preparation). Our results seem to be in contradiction with findings of Freduzzi et al. in A 2A receptor knockout mice with unilateral striatal dopamine denervation, which do not develop sensitization to L-DOPA-induced turning behavior [314] . The different results could be related to the developmental adaptations of the A 2A receptor knockout mouse brain, which includes a functional striatal hypodopaminergic activity (see above and refs. [240, 260] . Our preliminary results also indicate that once L-DOPAinduced behavioral sensitization is established, it cannot be reversed by A 2A receptor agonists. Thus, although A 2A receptor antagonists could be useful in the initial stages of Parkinson's disease (as discussed above), A 2A receptor agonists could be useful in late stages, to avoid the development of L-DOPA-induced dyskinesia. Obviously, in this case enough concomitant D 2 receptor agonism should be obtained in order to overcome the A 2A receptor agonistmediated decrease in affinity of D 2 receptors, and, therefore, the decrease in L-DOPA potency (see above). Finally, mGlu 5 receptors could also be a therapeutic target in sensitization to psychostimulants and L-DOPA-induced dyskinesias. In fact, there is a marked reduction in the striatal mGlu 5 receptor mRNA expression in rats sensitized to the motor activating effects of amphetamine [315] .
GENERAL DISCUSSION
The evidence for subtle and complex receptor-receptor interactions suggests a new dimension to neuronal signaling. Two isues will be briefly discussed before introducing new possibilities for drug development.
GPCR Characterization
As mentioned in the Introduction, no clearcut criteria are presently available for an objective classification of GPCRs into distinct families. The criterion used to date is based on amino acid sequence differences. Obviously this is an important criterion, but from a functional standpoint the important aspect of a protein is its steric structure, which cannot be univocally deduced from its amino acid sequence. Thus, it could be important to propose other criteria based on the tertiary structure of the receptor. We suggest the following two criteria:
The presence of "plastic" domains capable of carrying out a particular function, without considering the amino acid sequence of such domains. To clarify this point, one example is the extracellular domain of Family III GPCR, which forms two distinct lobes facing each other separated by a cavity where the ligand binds. Domains capable of such a function are present in GPCRs that do not have the same amino acid sequence. In fact, it has been found in mGlu, GABA B and in calcium sensing receptors.
The shared high affinity for some membrane-associated molecules among different GPCRs. Thus, the high affinity interaction of more GPCRs with one and the same membrane-associated molecule could also help in giving a criterion for a "steric" molecular classification. This criterion is similar to the one used for the pharmacological classification of receptors where the high affinity for a ligand, e.g. serotonin, led to the term "serotoninergic receptors", before the knowledge of the molecular structure of the receptors.
These criteria (besides amino acid sequence similarities and pharmacological characterization) could lead to a tentative "taxonomy" of GPCRs that could have great relevance for discovering functionally relevant classes of GPCRs. This taxonomy should distinguish GPCRs by similarities in function and would mainly consider GPCRs to be "analogous" (evolutionary definition of the term: a character shared by a set of species but not present in their common ancestor), instead of "homologous" (evolutionary definition of the term: a character shared by a set of species and present in their common ancestor).
Possible Meaning of Receptor Internalization
The functional importance of the internalization process has not been fully clarified. It may be surmised that cells use different "fingerprints" to allow their intracellular mechanisms to know which receptors or receptor complexes have been activated by the extracellular signals. The first one may be the special "cocktail" of enzymatic cascades activated in a differential way by the ligands acting on the receptors or on the receptor complexes. However, this may lead to incomplete information since similar (but not identical) activations can be triggered by ligands interacting with different receptors or receptor complexes. We put forward the hypothesis that the real "fingerprint" of actively transducing receptors is the internalization process of the receptors and of the receptor complexes bound to the respective ligands. It is suggested that special decoding mechanisms of this intracellular internalized message will be discovered that will be shown to have relevant roles both for the tuning of the neuronal function according to the functional match between the extracellular signals and the receptors on the plasma membrane and, possibly, also for the long-term memory trace formation [316] .
Possible New Strategies for Drug Development
This is a vast subject that is still mainly open to speculations and far from a concrete realization [316] . However, some observations can be made on the basis of a few points that have been discussed in the previous parts of this paper. From a general standpoint the target of drug development might not only be any longer the binding pocket for the neurotransmitter. At least five other important strategies can be mentioned:
Pharmacologically-induced alterations of the microenvironments with which the receptors are in contact. These alterations could affect formation or disruption of receptor complexes as well as their interactions with other membraneassociated proteins. Possible therapeutical interventions could take place by acting not directly on the molecular complex, but rather in one or more of the environments in contact with it. Obviously, alterations in the receptor microenvironments could also be studied to discover pathogenetic mechanisms until now ignored.
To prevent the interactions between receptors or receptors and membrane-associated proteins by altering at least one of the two interacting protein interfaces (e.g., by a drug that prevents the match by localizing at the interfaces of the receptors).
To shift the protein-protein interaction towards the formation of a different (inactive) complex (e.g., by favoring the matching between two different interfaces of the two partners).
To favor the interaction of one of the interacting proteins towards the formation of an active complex.
To modulate the process of receptor internalization. If the hypothesis mentioned above has some fine counterpart, this approach may also lead to the development of drugs that modulate neuronal function, and also the formation of longterm memory stores.
Finally, to act in a predictable way on protein-protein interactions is a difficult task. Discontinuous sequences located in distant parts of the proteins seem to be involved in protein-protein interactions. Thus, it is difficult to develop low molecular weight molecules capable of disrupting the protein interfaces that match or capable of favoring a functionally significant matching. The most straightforward strategy to develop a molecule that antagonizes a proteinprotein interaction is that of reproducing the essential features of one of the two partner proteins in a smaller protein which consequently interferes with the complex formation. Nevertheless, proteins, even of a reduced size, are still too large to be currently used as drugs. This could be overcome by developing small peptides or peptidomimetic molecules.
G-protein-coupled receptors form homomers and heteromers; agonist-induced conformational changes within interacting receptors of the oligomer modify their pharmacology, signalling and/or trafficking. When these receptors are activated, the oligomers rearrange and cluster and a novel mechanism of receptoroperation regulation by oligomer intercommunication is possible. This intercommunication would be assisted by components of the plasma membrane and by scaffolding proteins. Receptor cross-sensitization, crossdesensitization and novel, integrated receptor responses can then develop between oligomeric receptor complexes of the cluster without direct contact between them. This concept gives a new perspective to the understanding of neurotransmission and neuronal plasticity.
Previously, heptaspanning membrane, or G-proteincoupled, receptors were considered monomeric proteins that interact only with G proteins. However, it has become clear over the past four years that heptaspanningmembrane receptors are oligomeric structures formed not only by receptor homo-and hetero-dimers, but also a variety of proteins that interact both along the plane of the membrane (horizontal interactions) and across the plane of the membrane (from the extracellular to the intracellular side; vertical interactions). Furthermore, there is clear evidence that agonists induce a marked rearrangement of heptaspanning-membrane receptors in the plasma membrane.
Consideration of oligomerization and ligand-induced rearrangement (aggregation or clustering) of receptors provides new insight into our understanding of the mechanisms underlying the regulation of receptor function. Oligomeric complexes that come together in protein clusters form supramolecular structures in the plasma membrane that, together with scaffolding proteins, condition the behaviour (e.g. pharmacology, signalling and trafficking) of individual oligomeric receptor complexes.
In this process it should be considered that the plasma membrane is not an isomorphic structure, but a structure made by membrane domains with defined composition and chemical -physical characteristics (e.g. lipid rafts). In this article we comment on the existence of receptor regulation through direct protein -protein interactions within the oligomers, and propose intercommunication between proteins in oligomers that are not interacting directly but are present in the same cluster.
The conformational changes that are transferred through direct receptor-receptor and receptor-protein interactions constitute the first level of regulation of receptor function (Fig. 1) . The second level of regulation is proposed to occur via indirect interactions between different oligomeric receptor complexes, and are modulated by agonist-induced aggregation of such complexes (Fig. 2) . This regulation between non-interacting receptors in clusters is proposed to take place through intramembrane lipids and scaffolding proteins, involving conformational changes in a set of molecules in the membrane Oligomerization: the first level of regulation Heteromeric complexes The dimerization of membrane receptors (which was first demonstrated for the tyrosine kinase receptor superfamily) can be essential for signal transduction, and involves autophosphorylation and enhancement of agonist affinity [1, 2] . It was long assumed that heptaspanningmembrane receptors were isolated monomers despite the hypothesis that they interacted [3 -6] .
Interactions between heptaspanning-membrane receptors -which can be homo-or hetero-meric -are crucial to understand the varied functional cross-talk that has been observed, especially for neurotransmitter receptors. These functional interactions can be either antagonistic or agonistic, that is, signalling through one receptor can be enhanced or depressed while, simultaneously, the other receptor is being activated [5, [7] [8] [9] . This has key physiological consequences, especially in neurological diseases (see [5] ).
Heptaspanning-membrane receptors also interact with intracellular components; the best-characterized heterotypic interaction is with b-arrestins. In most instances, b-arrestins are required for receptor desensitization and internalization. The interaction between b-arrestins and these receptors also triggers the extracellular signalregulated kinases (ERK) cascade in which b-arrestins can behave both as agonist-regulated molecular adapters and as scaffolds [10] , thus allowing activated ERKs to target specific subcellular domains [11] . An increasing number of proteins also behave as modulating (receptoractivity modifying proteins; RAMPs) or scaffolding proteins for heptaspanning-membrane receptors [5,7 -9] , but their description is beyond the scope of this article.
The interaction between a receptor and the enzyme that degrades its physiological ligand is paradigmatic; two examples of receptor-enzyme interactions have been revealed. The chemokine receptor CXCR4 interacts with a type II membrane protein with dipeptidyl peptidase IV activity. This protein -also known as activation antigen CD26 -metabolizes the chemokine recognized by CXCR4, thus modulating the signal [12, 13] . CD26 cleaves the two N-terminal amino acids of the ligand, SDF1a, to render another ligand with different chemo-attractant and anti-HIV activity. This suggests that among the variables influencing the final activity of SDF1a, the amount of enzyme present, the K M (for peptidase activity), the K D (for receptor binding) and the initial concentration of the ligand are the most relevant. It would also be useful to find out whether the CD26-CXCR4 interaction modifies the dipeptidyl peptidase IV activity of CD26. Such regulation would lead to an altered availability of the ligand at the level of the receptor micro-environment, with reduced presence upon increases of peptidase activity. The second example is the interaction of adenosine deaminase (ADA) with two subtypes of adenosine receptors (A 1 and A 2B ) [14, 15] . Two aspects have to be considered in this interaction: one dependent and the other independent of the enzymatic activity (see below).
Adenosine A 1 receptors as a paradigm Here, we mainly discuss receptor homomers and heteromers that, through conformational changes, modulate the binding properties, G-protein coupling and receptor trafficking of one another [5,7 -9] .
Along the plasma membrane (horizontal plane), the most recently described protein -protein interactions involve homo-or hetero-dimers. Non-linear Scatchard plots, which are used to analyze ligand binding to heptaspanning-membrane receptors, have been explained by assuming various degrees of coupling between monomeric receptors and G proteins. Because receptors are now known to form dimers by directly interacting with each other, it is no longer necessary to include the interacting G proteins in the equation. The binding behaviour of heptaspanning-membrane receptors can be easily interpreted assuming that there is negative (or positive) cooperativity in binding, that is, after the binding of one ligand molecule to a receptor, the next molecule binds to the second receptor of the dimer with less (or higher) affinity (Fig. 1) . In fact, the presence of dimers justifies why agonists apparently modify the percentage of receptors with high affinity [16] . This is the case in the cooperativity displayed by oligomeric enzymes, which results from the conformational changes that occur when the ligand is bound to one of its active sites. A similar hypothesis can be suggested for heterodimers formed by two heptaspanning-membrane receptors (Fig. 1) . In fact, we have shown in cells co-expressing adenosine A 1 receptors (A 1 R) and dopamine D 1 receptors (D 1 R) that agonists for A 1 R inhibit the binding of dopamine analogues to D 1 R [17] . In analogy, the adenosine A 2A receptor (A 2A R) agonist decreases agonist binding to D 2 dopamine receptors (D 2 R) in the A 2A R-D 2 R heteromers [18] . Antagonism or synergism (e.g. in A 1 R-metabotropic glutamate receptor 1a heteromers [19] ) can, in part, be caused by cross-talk at the level of second messengers. In fact, the physiological adenosine-dopamine antagonism existing in striatum (e.g. demonstrated in enhancement of dopamine-receptormediated locomotion by treatment with adenosine-receptor antagonists [17] ) can be partly because activation of D 1 R leads to increases in cAMP, whereas activation of A 1 R leads to decreases in cAMP. However, the effect on the kinetics of ligand binding, which is also relevant to understand the physiological antagonisms detected, can be attributed almost exclusively to conformational changes transmitted within the intercommunicating receptor molecules. Heteromerization can also modify the pharmacology of interacting receptors [5, 20] , which offers great potential for designing novel drugs. Across the membrane (vertical to the plane of the membrane), A 1 Rs interact with both intracellular proteins that are not directly involved in signalling cascades and also with proteins that have an extracellular topology. Are these direct interactions relevant for receptor function? The heat-shock cognate protein hsc73 was identified as a cytosolic component that interacts with the third intracellular loop of A 1 R. As demonstrated by affinity chromatography and a biosensor-based technique (surface plasmon resonance), purified A 1 Rs interact specifically with hsc73 with a nanomolar dissociation constant (0.5^0.1 nM) [21] . The hsc73 -A 1 R interaction markedly reduces the affinity of A 1 R agonist and antagonist ligands, and prevents the activation of G proteins, as deduced from [ 35 S]GTPgS binding assays. The effect on A 1 R-agonist binding was stronger than that exerted by GTP analogues (which uncouple receptors from G proteins), and was completely prevented by ADA (a protein that interacts with the extracellular domains of A 1 R). Therefore, the binding of ADA to the extracellular side of A 1 R leads to conformational changes that either prevent the binding of the hsc73 to the intracellular side of A 1 R, or block the effects of the hsc73 -A 1 R binding.
A 1 R and caveolin also interact. In several cell lines, A 1 R are homogeneously distributed in the absence of ligand, but in the presence of agonist they concentrate in rafts that are cholesterol-rich specialized regions of the membrane [22, 23] . The C-terminal region of A 1 R has a consensus motif for interaction with caveolin (a protein enriched in caveolae), which are flask-shaped rafts. It is not known whether this interaction affects ligand binding, but it is crucial for receptor internalization -at least, it is in cells in which A 1 R internalization does not occur via clathrincoated vesicles [22, 23] . Although it has long been believed that heptaspanning-membrane receptors internalize via clathrin-enriched vesicles, recent evidence indicates that these receptors can also follow a clathrin-independent, caveolin-dependent internalization pathway [22 -24] . It is of interest to note that A 1 R and ADA can co-internalize via a caveolin-dependent mechanism that ends up in the endosomal compartment, where differential sorting takes place followed by independent recycling towards the cell surface [23, 25] . Details of this trafficking mechanism are being examined to fully understand the physiological role of the interaction between A 1 R and caveolin.
In addition, A 1 R interact with ADA across the plane of the membrane. The binding of [ 3 H]-2-chloroadenosine to A 1 R in rat brain membranes was first studied in two laboratories; binding in the absence or presence of ADA -single (low-affinity) or two binding (low-and highaffinity) sites, respectively [26] [27] [28] [29] . The appearance of a high-affinity-binding site in the presence of ADA was explained either by the disappearance of endogenous adenosine -which behaves as a competitor of A 1 R agonists -or by the assumption that ADA has an extracatalytic high-affinity-binding site for 2-chloroadenosine -which is not consistent with the X-ray structure of the enzyme [30] . Now, sufficient evidence supports a functional coupling between A 1 R and ADA. In fact, without this direct interaction A 1 R display a low affinity for agonists and can not be activated. The enzymatic activity of ADA is not necessary for this co-stimulatory role because the effect is still detected when adenosine deaminase activity is completely abolished. It should be noted that the A 1 R-D 1 R-mediated dopamine-adenosine antagonism requires interaction between A 1 R and ADA. Therefore, ADA regulates the binding of dopamine to D 1 R through A 1 R without directly contacting D 1 R [31] .
It remains to be investigated whether ADA enzymatic activity is modified by this ADA-A 1 R interaction. A recent report points to strong and variable changes in ADA-specific activity upon binding to dipeptidylpeptidase IV, which can also anchor ADA in membranes [32] . A similar mechanism of enzyme regulation in ADA -A 1 R complexes might be particularly interesting because ADA and A 1 R are internalized together by a caveolae-dependent mechanism. As reported by Lefkowitz and colleagues, signalling is often maintained in internalized vesicles that contain heptaspanning-membrane receptors [11, 24] . Thus, a reduction in ADA activity might lead to the maintenance of the signal produced by adenosine until both A 1 R and ADA reach the endosomal compartment, where they are differentially sorted and separately recycled to the cell surface.
Clustering: the second level of regulation Interactions among multiple heteromeric complexes Oligomers containing heptaspanning-membrane receptors, enzymes and other RAMPS, redistribute in the membrane and give rise to clusters when activated by hormones or neurotransmitters [17, [33] [34] [35] . Clusters arise from a marked redistribution of proteins to an area of the plasma membrane. There is a controversy as to whether the state of aggregation of receptors, for example, formation of heterotrimers or heterotetramers, increases with clustering. It seems that in cells expressing recombinant receptors, the degree of heteromerization does not vary with clustering, although this remains to be confirmed in unmodified cells. Irrespective of this, our hypothesis is that individual heptaspanning-membrane receptors present in the heteromers intercommunicate with each other through membrane lipids and intracellular scaffolds. Although the event of clustering has not received sufficient attention to date, we postulate that it constitutes a higher level of heptaspanning-membrane receptor and membrane enzyme regulation. Receptors (or enzymes interacting with them) might be regulated by other receptor molecules in the interacting complexes and also by other molecules that do not interact physically, but communicate with them in the cluster. The occurrence of clustering clearly suggests that heptaspanning-membrane receptors generate high-order molecular structures, in which multimers of the receptors form functional complexes. Clusters define a nested hierarchical level of organization in which a more refined behaviour can be envisioned. Thus, the regulation produced by these superstructures is at a higher level than that associated with an 'isolated' heteromeric-receptor complex system [36] .
I. Ligand binding
We believe that the ligand-induced conformational changes of a receptor in a cluster transmit information within the cluster that slightly alters the thermodynamic properties (and so the K D ) of all proteins in that cluster. These conformational changes reflect the energy landscape of the clustered proteins (Fig. 2) .
In 1996, we proposed a model that takes into account that various heptaspanning-membrane receptor molecules undergo, as a result of ligand binding, a cascade of discrete conformational transitions that affect their affinity. The cluster-arranged cooperative model (CACM) [33] is based on the hypothesis that heptaspanning-membrane receptors are not isolated proteins, but that they communicate with each other by components of the membrane and scaffolds. This intercommunication between molecules was regarded, at that time, as the basis of the observed cooperativity, and its participation in the multiple processes involved in ligand-induced desensitization was suggested. The validity of the model was shown with A 1 Rs [33] , for which clustering probably alters the conformation of the receptor in such a way that it decreases the affinity for the agonist. This is also the reason why the model was named the cluster-arranged cooperative model, and why all the molecules were assumed to intercommunicate within a patch in the membrane. Therefore, the CACM might be a suitable model for how higher-order structures affect receptor and enzyme functions.
Let us consider the heteromeric complexes A, B and C in a given cluster. When the first ligand binds to a receptor in A, not only are other enzyme or receptor molecules in A affected (by negative or positive cooperativity), but the kinetics for ligand binding to, for instance, receptors present in B and C, also change, as do their K D values. These slight modifications in K D for receptors in B and C are a function of the concentration of the first agonist interacting with the cluster. When a receptor in A is activated within the cluster, it can be assumed that this first ligand interaction decreases the K D for a receptor in B (and/or C). A lower concentration of specific ligands for that receptor in B (and/or C) would be then sufficient to trigger its signalling cascade. In this way, sensitization could occur. Obviously, the opposite could also happen: if activation of a receptor in A increases the K D for a receptor in B (and/or C), a higher concentration of agonists for that receptor in B (and/or C) is needed to trigger signalling. In these circumstances, desensitization or even anergy (no signalling) could take place. Furthermore, it is possible that the situation could be even more complex. Consider, for instance, that the first agonist decreases the K D for a receptor in B, and increases the K D for a receptor in C. This would be a mechanism for an integrative response (specialization) because a hormone or neurotransmitter would simultaneously sensitize a receptor in B and desensitize a receptor in C, which might represent a process of learning (Fig. 3) . According to this model, the first signal arriving at the membrane cluster would condition the future behaviour of all receptors in the cluster. This could help explain the molecular basis of complex phenomena such as neuronal plasticity at the membrane level (i.e. information handling among heteromeric receptor complexes in the agonist-induced receptor cluster).
II. Molecular rearrangements
Apart from changing affinity, signalling could also be conditioned by the constraints of clustering. In a given area of the cell surface, the two-dimensional 'concentration' of a receptor in the absence of the ligand could be low because the receptors are homogeneously distributed. In response to the agonist, the two-dimensional 'concentration' and distribution of receptors in the area of membrane change as the cluster forms. This was shown for A 1 R [33, 34] , A 1 R-D 1 R heterodimers [17] and A 2A R-D 2 R heterodimers [35] in cell lines and neurones. This molecular rearrangement might be produced by two events: conformational changes in the proteins at the horizontal level and the action of scaffolding proteins such as b-arrestin, caveolin, and others (e.g. those linking receptors to the cytoskeleton), which guide receptors in this clustering journey. Depending upon the cell (each cell has it own set of receptors expressed on the membrane) and the type of activated receptors, cluster composition and molecular rearrangement (geometry and distances) can be postulated to change. This leads to differences in Fig. 3 . Scheme of how an agonist ligand (symbolized by a hat) for one receptor (symbolized by a face) might sensitize or desensitize other receptors for their transmitters in a cluster. According to the text, different types of receptors (light green, light blue and pink) exist in distinct homo-oligomeric complexes clustered in the same membrane area. 'Happy', round receptors with hats on would be those having a high affinity for the agonist and, thus, high signalling. 'Sad', square receptors with tilted hats would be those having a low affinity for the agonist and low signalling. signalling from cell to cell and even within the same cell when activated by distinct sets of hormones or neurotransmitters. This redistribution should be relevant for integration of signalling, which would vary according to the location of the activated receptors in the membrane (Fig. 4) .
It should be noted that at this second level of regulation, the plasma membrane itself transduces conformational changes in neighbouring elements. This can be achieved, at least in part, by modifications, for example, in membrane lipids, which condition receptor pharmacology; this is important to understand changes in signalling in cells whose membrane fluidity is altered when they become tumorigenic. Moreover, there is evidence that agonists acting on adenosine receptors alter membrane microviscosity in myelin [37] and neutrophils [38] . Because each cell has its own set of receptors and interacting molecules, clustering and ligand-induced changes in membrane structure give rise to specific molecular rearrangements of the receptors, interacting proteins and underlying signalling machinery. The variety of molecular networks in the clusters might be described as several systems of 'crystallization' in the patch. Different processes of freezing the receptors within those molecular networks might lead to the formation of memory traces in the membrane [39] .
In a system of interconnected binary elements, some of the elements might freeze in fixed states of activity (either active or inactive) [40] . According to our hypothesis, a cluster of frozen elements in a receptor mosaic might represent a mechanism for the maintenance of a constant input of a neurone and, hence, might play a role in the learning process (where the input of a neurone is likely to remain constant for a period of time) [39] , which sometimes is simply represented by a phenomenon of sensitization and desensitization. Even for a single cell, the arrangement of the receptors (or enzymes) in the cluster might depend on the type of receptor (or enzyme) that 'guides' the clustering, that is, arrangement is dependent on the type of receptor activated first, which receptor is activated second and so on. It seems evident that the location of the receptors in the membrane after activation and the clustering influences the physiological effect. Thus, the concentration, the degree of activation and the arrangement of receptors in the clusters could condition signalling in such a way that signalling might differ from cell to cell and even within the same cell (among distinct locations in a given cell) depending on the spatialtemporal course of activation. This novel concept provides a new perspective in understanding neurotransmission and neuronal plasticity. 
